002022 Stock Overview
Researches and develops, produces, and sells in vitro diagnostic reagents, medical testing equipment and other products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Shanghai Kehua Bio-Engineering Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.56 |
| 52 Week High | CN¥11.85 |
| 52 Week Low | CN¥5.05 |
| Beta | 0.38 |
| 11 Month Change | 4.79% |
| 3 Month Change | 20.81% |
| 1 Year Change | -30.36% |
| 33 Year Change | -54.16% |
| 5 Year Change | -39.82% |
| Change since IPO | -70.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002022 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.5% | -2.6% | -2.1% |
| 1Y | -30.4% | -20.9% | 2.8% |
Return vs Industry: 002022 underperformed the CN Biotechs industry which returned -17.3% over the past year.
Return vs Market: 002022 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 002022 volatility | |
|---|---|
| 002022 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 002022 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002022's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,151 | Ming Li | www.skhb.com |
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic reagents, medical testing equipment and other products in China and internationally. It offers signature products, including immunoassay & clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management, and automated comprehensive solutions for nucleic acid blood screening; automatic modular and clinical chemistry analyzer; automatic chemiluminescence immunoassay analyzers; and CLIA reagents tests. The company also provides automatic microplate reader, microplate washer, and enzyme-linked immunoassay reagents; diagnostic kit for HIV and SARS-CoV-2 IgM/IgG antibody; and fully automated nucleic acid blood screening laboratory and molecular diagnostics solutions.
Shanghai Kehua Bio-Engineering Co.,Ltd Fundamentals Summary
| 002022 fundamental statistics | |
|---|---|
| Market cap | CN¥3.29b |
| Earnings (TTM) | -CN¥336.20m |
| Revenue (TTM) | CN¥1.87b |
1.8x
P/S Ratio-9.8x
P/E RatioIs 002022 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002022 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.87b |
| Cost of Revenue | CN¥1.24b |
| Gross Profit | CN¥629.77m |
| Other Expenses | CN¥965.97m |
| Earnings | -CN¥336.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 33.60% |
| Net Profit Margin | -17.94% |
| Debt/Equity Ratio | 8.6% |
How did 002022 perform over the long term?
See historical performance and comparison